Rafagen
2007
FOUNDED
OOB
STATUS
Out of Business
LATEST DEAL TYPE
Description
Developer of next generation gene expression systems designed to solve problems in molecular therapeutics. The company's gene expression systems are developed with genetically engineered CHO cells and also provides services like gene cloning, codon optimization, gene synthesis, cell culture scale up, cell based assays and fow cytometry, enabling physicians to kill cancer cells with the highest possible efficiencies while leaving normal cells unharmed.
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Primary Office
- 9700 Great Seneca Highway
- Suite 191
- Rockville, MD 20850
- United States
+1 (301) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Rafagen’s full profile, request a free trial.
Rafagen Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 01-Aug-2016 | 00000 | Completed | Out of Business | ||
| 4. Grant | 04-Nov-2010 | 00000 | Completed | Startup | ||
| 3. Corporate | 16-Dec-2009 | 00000 | Completed | Startup | ||
| 2. Early Stage VC | 01-Apr-2009 | $237K | Completed | Startup | ||
| 1. Accelerator/Incubator | 09-Jul-2008 | $237K | $237K | Completed | Startup |
Rafagen Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Sung Hahm Ph.D | Co-Founder, President & Chief Executive Officer | ||
| Ja Koo Ph.D | Co-Founder & Chief Technology Officer |
1 Former Executive
You’re viewing 2 of 3 executives. Get the full list »